United States — Food and Drug Administration & ImmunityBio
5 shared events · Importance 4 · Last updated Jun 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.
ImmunityBio: ImmunityBio is the defendant in multiple securities class action lawsuits due to alleged misleading statements about its drug Anktiva, which caused its stock price to fall significantly. The company faces investigations and potential financial penalties.
Apr 02, 2026 · 132 articles
Tech
ImmunityBio: ImmunityBio developed N-803 (Anktiva), which was used in combination with MiNK Therapeutics' Agent 797, potentially increasing the visibility and market for their product.
May 20, 2026 · 9 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and ImmunityBio interact across events, view sentiment trends, and discover connected entities.
Open Dashboard